Show simple item record

dc.creatorMiljković, Branislava
dc.creatorPokrajac, Milena
dc.creatorTimotijević, Ivana
dc.creatorVaragić, V.M.
dc.date.accessioned2019-09-02T10:49:30Z
dc.date.available2019-09-02T10:49:30Z
dc.date.issued1996
dc.identifier.issn0378-7966
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/142
dc.description.abstractAlthough many attempts have been made, to date no convincing evidence exists of a relationship between plasma concentrations of amitriptyline (AT), its active metabolite nortriptyline (NT) and clinical response. Fifteen patients with primary depression (according to DSM-IV) were divided in two groups according to given doses: (I) 6 patients received 3 x 50 mg of AT daily; and (II) 9 patients received 3 x 25 mg of AT daily, for 6 weeks. The clinical status was determined with Hamilton Depression Rating Scale. Both investigated doses were therapeutically effective. AT and NT plasma concentrations were assayed by high performance liquid chromatography. Following administration of 3 x 50 mg of AT daily, the correlation of concentrations of AT, NT, total AT+NT and clinical response were r(AT) = -0.702 (P lt 0.1), r(NT) = -0.761 (P lt 0.1), r(AT+NT) = -0.741 (P lt 0.1). The linear and very high correlation were also present with concentrations of AT, NT, total AT+NT and clinical response in depressive patients on 3 x 25 mg AT daily: r(AT) = -0.785 (P lt 0.02), r(NT) = -0.811 (P lt 0.01), r(AT+NT) = -0.848 (P lt 0.01). Our results support a high correlation between AT/NT plasma concentrations and clinical response indicating that therapeutic monitoring of AT and its metabolite, NT, can provide eventual clinical response.en
dc.publisherMedecine Et Hygiene, Geneva 4
dc.rightsrestrictedAccess
dc.sourceEuropean Journal of Drug Metabolism and Pharmacokinetics
dc.subjectAmitriptylineen
dc.subjectClinical responseen
dc.subjectCorrelationen
dc.subjectNortriptylineen
dc.subjectPatientsen
dc.titleClinical response and plasma concentrations of amitriptyline and its metabolite-nortriptyline in depressive patientsen
dc.typearticle
dc.rights.licenseARR
dcterms.abstractТимотијевић, Ивана; Миљковић, Бранислава; Покрајац, Милена; Варагић, В.М.;
dc.citation.volume21
dc.citation.issue3
dc.citation.spage251
dc.citation.epage255
dc.citation.other21(3): 251-255
dc.identifier.wosA1996VZ02200009
dc.identifier.doi10.1007/BF03189722
dc.identifier.pmid8980924
dc.identifier.scopus2-s2.0-0030462288
dc.identifier.rcubconv_4419
dc.type.versionpublishedVersion


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record